{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T15:57:31Z","timestamp":1790870251625,"version":"4.1.0"},"reference-count":30,"publisher":"American Association for Cancer Research (AACR)","issue":"10","license":[{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["aacrjournals.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,10,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Purpose:<\/jats:title>\n                    <jats:p>PF-07062119 is an anti-GUCY2C\/anti-CD3\u03b5 bispecific Fc antibody designed to elicit systemic antitumor immunity. This phase I, first-in-human study evaluated the safety, tolerability, pharmacokinetics (PK), pharmacodynamics, immunogenicity, and antitumor activity of PF-07062119 as monotherapy and in combination with sasanlimab or bevacizumab in patients with advanced gastrointestinal (GI) cancers expressing GUCY2C.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Patients and Methods:<\/jats:title>\n                    <jats:p>Patients received escalating doses of PF-07062119 (45\u20133,700 \u03bcg SC) in part 1A. In part 1B, PF-07062119 was administered with either sasanlimab (300 mg SC) or bevacizumab (5 mg\/kg i.v.). Primary endpoints were safety and tolerability; secondary endpoints included PK, immunogenicity, and efficacy.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>A total of 79 patients were enrolled. In part 1A, maximum tolerated dose without a priming dose was 800 \u03bcg. Dose-limiting toxicities observed at this level were grade 3 cytokine release syndrome (CRS), colitis, and diarrhea. A 400 \u03bcg priming dose with premedication reduced CRS incidence, and recommended dose for expansion was 2,100 \u03bcg. Treatment-related grade 3\/4 treatment-emergent adverse events (TEAE) were observed in 27 (34.2%) patients, with no grade 5 treatment-related TEAEs. Diarrhea remained the most clinically significant toxicity in part 1A. Combination therapy in part 1B did not result in significant additional toxicity. PK analyses demonstrated dose-proportional increases in exposure. The overall response rate was 2.5% across all cohorts.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions:<\/jats:title>\n                    <jats:p>PF-07062119 monotherapy demonstrated a generally tolerable safety profile within the context of this early-phase study with evidence of clinical activity in patients with advanced\/metastatic GI cancers.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Significance:<\/jats:title>\n                    <jats:p>GUCY2C is universally expressed in colorectal cancer and ectopically expressed by other GI cancers. In this first-in-human phase I study, PF-07062119, an anti-GUCY2C\/anti-CD3\u03b5 bispecific Fc antibody, demonstrated a generally tolerable safety profile with evidence of antitumor activity in patients with advanced GI cancers.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1158\/2767-9764.crc-26-0101","type":"journal-article","created":{"date-parts":[[2026,9,4]],"date-time":"2026-09-04T19:01:23Z","timestamp":1788548483000},"page":"2299-2310","update-policy":"https:\/\/doi.org\/10.1158\/crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["A Phase I Study of PF-07062119, an Anti-GUCY2C\/Anti-CD3 Bispecific Fc Antibody, in Patients with Advanced Gastrointestinal Cancers"],"prefix":"10.1158","volume":"6","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6554-5488","authenticated-orcid":false,"given":"Marwan","family":"Fakih","sequence":"first","affiliation":[{"name":"1Department of Medical Oncology and Therapeutics Research, City of Hope Comprehensive Cancer Center, Duarte, California."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2042-6829","authenticated-orcid":false,"given":"Toshihiko","family":"Doi","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/03rm3gk43","id-type":"ROR","asserted-by":"publisher"}],"name":"National Cancer Center Hospital East 2 Department of Experimental Therapeutics, , Kashiwa, Japan."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6322-9721","authenticated-orcid":false,"given":"Anthony","family":"Tolcher","sequence":"additional","affiliation":[{"name":"3New Experimental Therapeutics (NEXT) Oncology, San Antonio, Texas."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8721-1609","authenticated-orcid":false,"given":"David","family":"Hong","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/04twxam07","id-type":"ROR","asserted-by":"publisher"}],"name":"The University of Texas MD Anderson Cancer Center 4 Division of Cancer Medicine, Department of Investigational Cancer Therapeutics, , Houston, Texas."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9244-2057","authenticated-orcid":false,"given":"Jeanne","family":"Tie","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/02a8bt934","id-type":"ROR","asserted-by":"publisher"}],"name":"Peter MacCallum Cancer Centre 5 Department of Medical Oncology, , Melbourne, Australia."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2349-0885","authenticated-orcid":false,"given":"Wells","family":"Messersmith","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/03wmf1y16","id-type":"ROR","asserted-by":"publisher"}],"name":"University of Colorado School of Medicine 6 Division of Medical Oncology, Department of Medicine, , Aurora, Colorado."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5807-8458","authenticated-orcid":false,"given":"Takafumi","family":"Koyama","sequence":"additional","affiliation":[{"name":"7Department of Experimental Therapeutics, National Cancer Center Hospital, Tokyo, Japan."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2503-6133","authenticated-orcid":false,"given":"Lee","family":"Rosen","sequence":"additional","affiliation":[{"name":"8Division of Hematology-Oncology, Department of Medicine, UCLA Medical Center, Los Angeles, California."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2622-0901","authenticated-orcid":false,"given":"Joana","family":"Borlido","sequence":"additional","affiliation":[{"name":"9Cancer Immunology Discovery, Pfizer Inc., San Diego, California."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9083-6087","authenticated-orcid":false,"given":"Michael A.","family":"Damore","sequence":"additional","affiliation":[{"name":"10Translational Oncology, Pfizer Inc., San Diego, California."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-6827-7502","authenticated-orcid":false,"given":"Maria","family":"Delioukina","sequence":"additional","affiliation":[{"name":"11Oncology Early Clinical Development, Pfizer Inc., La Jolla, California."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-1654-960X","authenticated-orcid":false,"given":"Ioanna","family":"Cheronis","sequence":"additional","affiliation":[{"name":"11Oncology Early Clinical Development, Pfizer Inc., La Jolla, California."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-7276-2791","authenticated-orcid":false,"given":"Lee Noel","family":"Clark","sequence":"additional","affiliation":[{"name":"11Oncology Early Clinical Development, Pfizer Inc., La Jolla, California."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2111-0773","authenticated-orcid":false,"given":"Marzieh","family":"Golmakani","sequence":"additional","affiliation":[{"name":"12Oncology Late Stage Development, Pfizer Inc., San Diego, California."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-9909-6169","authenticated-orcid":false,"given":"Amy","family":"Jackson-Fisher","sequence":"additional","affiliation":[{"name":"10Translational Oncology, Pfizer Inc., San Diego, California."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-3652-4863","authenticated-orcid":false,"given":"Szu-Yu","family":"Tang","sequence":"additional","affiliation":[{"name":"11Oncology Early Clinical Development, Pfizer Inc., La Jolla, California."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6850-1045","authenticated-orcid":false,"given":"Cathy Cen","family":"Guo","sequence":"additional","affiliation":[{"name":"11Oncology Early Clinical Development, Pfizer Inc., La Jolla, California."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6607-0760","authenticated-orcid":false,"given":"Edmund J.","family":"Keliher","sequence":"additional","affiliation":[{"name":"13Worldwide Research and Development, Pfizer Inc., Cambridge, Massachusetts."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4420-1296","authenticated-orcid":false,"given":"Kevin","family":"Maresca","sequence":"additional","affiliation":[{"name":"13Worldwide Research and Development, Pfizer Inc., Cambridge, Massachusetts."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3047-2303","authenticated-orcid":false,"given":"Neil H.","family":"Segal","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/02yrq0923","id-type":"ROR","asserted-by":"publisher"}],"name":"Memorial Sloan Kettering Cancer Center 14 Division of Solid Tumor Oncology, , New York, New York."},{"name":"15Weill Cornell Medical College, New York, New York."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1086","published-online":{"date-parts":[[2026,10,1]]},"reference":[{"key":"2026100111214973900_bib1","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1111\/imr.12393","article-title":"Harnessing T cells to fight cancer with BiTE\u00ae antibody constructs\u2013past developments and future directions","volume":"270","author":"Klinger","year":"2016","journal-title":"Immunol Rev"},{"key":"2026100111214973900_bib2","doi-asserted-by":"publisher","first-page":"552","DOI":"10.1097\/cco.0000000000000869","article-title":"T-cell-engaging antibodies for the treatment of solid tumors: challenges and opportunities","volume":"34","author":"Baeuerle","year":"2022","journal-title":"Curr Opin Oncol"},{"key":"2026100111214973900_bib3","doi-asserted-by":"publisher","first-page":"e2400753","DOI":"10.1200\/PO-24-00753","article-title":"Expanding the therapeutic reach of chimeric antigen receptor T-cells and bispecific T-cell engagers across solid tumors","volume":"9","author":"Gerber","year":"2025","journal-title":"JCO Precis Oncol"},{"key":"2026100111214973900_bib4","doi-asserted-by":"publisher","first-page":"104752","DOI":"10.1016\/j.critrevonc.2025.104752","article-title":"Recent development in bispecific antibody immunotherapy for hematological malignancies","volume":"212","author":"Han","year":"2025","journal-title":"Crit Rev Oncol Hematol"},{"key":"2026100111214973900_bib5","doi-asserted-by":"publisher","first-page":"2063","DOI":"10.1056\/NEJMoa2307980","article-title":"Tarlatamab for patients with previously treated small-cell lung cancer","volume":"389","author":"Ahn","year":"2023","journal-title":"N Engl J Med"},{"key":"2026100111214973900_bib6","doi-asserted-by":"publisher","first-page":"1196","DOI":"10.1056\/NEJMoa2103485","article-title":"Overall survival benefit with tebentafusp in metastatic uveal melanoma","volume":"385","author":"Nathan","year":"2021","journal-title":"N Engl J Med"},{"key":"2026100111214973900_bib7","volume-title":"FDA approves tebentafusp-tebn for unresectable or metastatic uveal melanoma","author":"FDA","year":"2022"},{"key":"2026100111214973900_bib8","doi-asserted-by":"publisher","first-page":"e31686","DOI":"10.1371\/journal.pone.0031686","article-title":"GUCY2C opposes systemic genotoxic tumorigenesis by regulating AKT-dependent intestinal barrier integrity","volume":"7","author":"Lin","year":"2012","journal-title":"PLoS One"},{"key":"2026100111214973900_bib9","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1016\/j.tem.2013.01.001","article-title":"GUCY2C: at the intersection of obesity and cancer","volume":"24","author":"Kim","year":"2013","journal-title":"Trends Endocrinol Metab"},{"key":"2026100111214973900_bib10","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1007\/s12026-011-8253-7","article-title":"GUCY2C-targeted cancer immunotherapy: past, present and future","volume":"51","author":"Snook","year":"2011","journal-title":"Immunol Res"},{"key":"2026100111214973900_bib11","doi-asserted-by":"publisher","first-page":"14827","DOI":"10.1073\/pnas.93.25.14827","article-title":"Guanylyl cyclase C is a selective marker for metastatic colorectal tumors in human extraintestinal tissues","volume":"93","author":"Carrithers","year":"1996","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2026100111214973900_bib12","doi-asserted-by":"publisher","first-page":"e0189953","DOI":"10.1371\/journal.pone.0189953","article-title":"Consistent expression of guanylyl cyclase-C in primary and metastatic gastrointestinal cancers","volume":"12","author":"Danaee","year":"2017","journal-title":"PLoS One"},{"key":"2026100111214973900_bib13","doi-asserted-by":"publisher","first-page":"170","DOI":"10.1016\/j.humpath.2004.12.002","article-title":"Guanylyl cyclase C is a marker of intestinal metaplasia, dysplasia, and adenocarcinoma of the gastrointestinal tract","volume":"36","author":"Birbe","year":"2005","journal-title":"Hum Pathol"},{"key":"2026100111214973900_bib14","doi-asserted-by":"publisher","first-page":"201","DOI":"10.2217\/bmm-2020-0359","article-title":"Guanylyl cyclase C as a biomarker for immunotherapies for the treatment of gastrointestinal malignancies","volume":"15","author":"Flickinger","year":"2021","journal-title":"Biomark Med"},{"key":"2026100111214973900_bib15","doi-asserted-by":"publisher","first-page":"2188","DOI":"10.1158\/1078-0432.Ccr-19-3275","article-title":"A novel GUCY2C-CD3 T-cell engaging bispecific construct (PF-07062119) for the treatment of gastrointestinal cancers","volume":"26","author":"Mathur","year":"2020","journal-title":"Clin Cancer Res"},{"key":"2026100111214973900_bib16","doi-asserted-by":"publisher","first-page":"1425","DOI":"10.1093\/carcin\/20.8.1425","article-title":"Increased tight junctional permeability is associated with the development of colon cancer","volume":"20","author":"Soler","year":"1999","journal-title":"Carcinogenesis"},{"key":"2026100111214973900_bib17","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1111\/j.1749-6632.2000.tb05246.x","article-title":"Increased tight junction permeability can result from protein kinase C activation\/translocation and act as a tumor promotional event in epithelial cancers","volume":"915","author":"Mullin","year":"2000","journal-title":"Ann N Y Acad Sci"},{"issue":"16_Supplement","key":"2026100111214973900_bib18","doi-asserted-by":"publisher","first-page":"4549","DOI":"10.1158\/1538-7445.Am2020-4549","article-title":"Abstract 4549: evaluation of GUCY2c-CD3 bispecific targeting GI cancers in an orthotopic colorectal tumor model","volume":"80","author":"Yao","year":"2020","journal-title":"Cancer Res"},{"key":"2026100111214973900_bib19","doi-asserted-by":"publisher","first-page":"144","DOI":"10.1016\/j.yrtph.2017.09.001","article-title":"An FDA oncology analysis of CD3 bispecific constructs and first-in-human dose selection","volume":"90","author":"Saber","year":"2017","journal-title":"Regul Toxicol Pharmacol"},{"key":"2026100111214973900_bib20","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1177\/1740774509356002","article-title":"Summarizing historical information on controls in clinical trials","volume":"7","author":"Neuenschwander","year":"2010","journal-title":"Clin Trials"},{"key":"2026100111214973900_bib21","doi-asserted-by":"publisher","first-page":"512","DOI":"10.2967\/jnumed.119.229781","article-title":"First-in-humans imaging with 89Zr-Df-IAB22M2C anti-CD8 minibody in patients with solid malignancies: preliminary pharmacokinetics, biodistribution, and lesion targeting","volume":"61","author":"Pandit-Taskar","year":"2020","journal-title":"J Nucl Med"},{"key":"2026100111214973900_bib22","doi-asserted-by":"publisher","first-page":"941","DOI":"10.1007\/s11307-021-01621-0","article-title":"Preclinical evaluation of 89Zr-Df-IAB22M2C PET as an imaging biomarker for the development of the GUCY2C-CD3 bispecific PF-07062119 as a T cell engaging therapy","volume":"23","author":"Maresca","year":"2021","journal-title":"Mol Imaging Biol"},{"key":"2026100111214973900_bib23","doi-asserted-by":"publisher","first-page":"1350","DOI":"10.1158\/1535-7163.MCT-21-0073","article-title":"Targeting solid tumors using CD3 bispecific antibodies","volume":"20","author":"Crawford","year":"2021","journal-title":"Mol Cancer Ther"},{"key":"2026100111214973900_bib24","doi-asserted-by":"publisher","first-page":"1548446","DOI":"10.3389\/fonc.2025.1548446","article-title":"Improving CD3 bispecific antibody therapy in solid tumors using combination strategies","volume":"15","author":"Lloyd","year":"2025","journal-title":"Front Oncol"},{"key":"2026100111214973900_bib25","doi-asserted-by":"publisher","first-page":"4091","DOI":"10.1038\/s41467-024-48479-8","article-title":"CEA-CD3 bispecific antibody cibisatamab with or without atezolizumab in patients with CEA-positive solid tumours: results of two multi-institutional Phase 1 trials","volume":"15","author":"Segal","year":"2024","journal-title":"Nat Commun"},{"key":"2026100111214973900_bib26","article-title":"FDA grants accelerated approval to tarlatamab-dlle for extensive stage small cell lung cancer. Silver Spring (MD)","author":"Food and Drug Administration","year":"2024"},{"key":"2026100111214973900_bib27","doi-asserted-by":"publisher","first-page":"e005755","DOI":"10.1136\/jitc-2022-005755","article-title":"Efficacy and safety of lifileucel, a one-time autologous tumor-infiltrating lymphocyte (TIL) cell therapy, in patients with advanced melanoma after progression on immune checkpoint inhibitors and targeted therapies: pooled analysis of consecutive cohorts of the C-144-01 study","volume":"10","author":"Chesney","year":"2022","journal-title":"J Immunother Cancer"},{"key":"2026100111214973900_bib28","doi-asserted-by":"publisher","first-page":"e471716","DOI":"10.1200\/EDBK-25-471716","article-title":"Cell-based therapies in GI cancers: current landscape and future directions","volume":"45","author":"Nakayama","year":"2025","journal-title":"Am Soc Clin Oncol Educ Book"},{"issue":"16_suppl","key":"2026100111214973900_bib29","doi-asserted-by":"publisher","first-page":"2518","DOI":"10.1200\/JCO.2024.42.16_suppl.2518","article-title":"Phase I study of GUCY2C CAR-T therapy IM96 in patients with metastatic colorectal cancer","volume":"42","author":"Qi","year":"2024","journal-title":"J Clin Oncol"},{"key":"2026100111214973900_bib30","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1007\/s00280-023-04507-w","article-title":"A phase I, first-in-human study of TAK-164, an antibody-drug conjugate, in patients with advanced gastrointestinal cancers expressing guanylyl cyclase C","volume":"91","author":"Kim","year":"2023","journal-title":"Cancer Chemother Pharmacol"}],"container-title":["Cancer Research Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/aacrjournals.org\/cancerrescommun\/article-pdf\/doi\/10.1158\/2767-9764.CRC-26-0101\/3827289\/crc-26-0101.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/aacrjournals.org\/cancerrescommun\/article-pdf\/6\/10\/2299\/3834913\/crc-26-0101.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/aacrjournals.org\/cancerrescommun\/article-pdf\/6\/10\/2299\/3834913\/crc-26-0101.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T15:21:57Z","timestamp":1790868117000},"score":1,"resource":{"primary":{"URL":"https:\/\/aacrjournals.org\/cancerrescommun\/article\/6\/10\/2299\/788657\/A-Phase-I-Study-of-PF-07062119-an-Anti-GUCY2C-Anti"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10,1]]},"references-count":30,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2026,10,1]]}},"URL":"https:\/\/doi.org\/10.1158\/2767-9764.crc-26-0101","relation":{"is-supplemented-by":[{"id-type":"doi","id":"10.1158\/2767-9764.34046716","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.34046719","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.34046707","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.34046671","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.34046683","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.34046695","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.34046674","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.34046680","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.34046692","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.34046713","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.34046701","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.34046704","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.34046686","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.34046698","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.34046677","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.34046722","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.34046689","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.34046710","asserted-by":"object"}],"has-preprint":[{"id-type":"doi","id":"10.1158\/2767-9764.c.8748988","asserted-by":"object"}]},"ISSN":["2767-9764"],"issn-type":[{"value":"2767-9764","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,10,1]]}}}